{
    "abstract": "Hyperglycemia in hospitalized patients is associated with increased morbidity and mortality. Basal-bolus insulin therapy is the treatment of choice for most patients. The efficacy of an ultrarapid vs rapid-acting insulin in hospitalized patients with diabetes has not been evaluated. We assessed noninferiority in efficacy and safety of Fiasp vs aspart (Novolog) as part of a basal-bolus insulin regimen in noncritically ill patients with type 2 diabetes in a safety-net hospital.\nThis prospective, open-label, randomized trial included 137 patients with diabetes admitted to a non-intensive care unit setting. Subjects were treated with glargine at bedtime and either Fiasp or Novolog for prandial and correction insulin. Subjects were enrolled for a minimum of 4 or maximum of 6 meal boluses. Capillary blood glucose was used for insulin adjustment and a blinded Dexcom G6 Pro captured data for study analysis. The primary endpoint was time spent in sensor glucose range 100-180\u00a0mg/dL in the 4-hour postprandial period (assessed among 106 participants with \u2265 4 meals with a 4-hour postprandial period). Time spent in hypoglycemic ranges (<70, <54, <40\u00a0mg/dL) was assessed for safety.\nFour-hour postprandial time in range 100-180\u00a0mg/dL was 45% in the Fiasp group vs 36% in the Novolog group (P\u00a0=\u00a0.012; meeting prespecified noninferiority criteria). Other glycemic metrics were similar between groups with no difference in time spent in hypoglycemic ranges.\nFiasp provides noninferior postprandial glucose control in hospitalized patients with type 2 diabetes when compared to Novolog with no increase in rates of hypoglycemia.",
    "authors": [
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Sara M",
            "initials": "SM",
            "lastname": "Alexanian"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Michael C",
            "initials": "MC",
            "lastname": "Cheney"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Nicole L",
            "initials": "NL",
            "lastname": "Spartano"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Jenny C",
            "initials": "JC",
            "lastname": "Bello-Ramos"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Niyoti",
            "initials": "N",
            "lastname": "Reddy"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Aamir",
            "initials": "A",
            "lastname": "Malik"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Jonila",
            "initials": "J",
            "lastname": "Murati"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts.",
            "firstname": "Howard A",
            "initials": "HA",
            "lastname": "Wolpert"
        },
        {
            "affiliation": "Section of Endocrinology, Diabetes, Nutrition and Weight Management, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, Massachusetts. Electronic address: desteenk@bu.edu.",
            "firstname": "Devin W",
            "initials": "DW",
            "lastname": "Steenkamp"
        }
    ],
    "conclusions": "Fiasp provides noninferior postprandial glucose control in hospitalized patients with type 2 diabetes when compared to Novolog with no increase in rates of hypoglycemia.",
    "copyrights": "Copyright \u00a9 2024 AACE. Published by Elsevier Inc. All rights reserved.",
    "doi": "10.1016/j.eprac.2024.11.015",
    "journal": "Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists",
    "keywords": [
        "continuous glucose monitoring",
        "improving postprandial blood glucose",
        "inpatient management",
        "insulin administration"
    ],
    "methods": null,
    "publication_date": "2024-12-07",
    "pubmed_id": "39643003",
    "results": "Four-hour postprandial time in range 100-180\u00a0mg/dL was 45% in the Fiasp group vs 36% in the Novolog group (P\u00a0=\u00a0.012; meeting prespecified noninferiority criteria). Other glycemic metrics were similar between groups with no difference in time spent in hypoglycemic ranges.",
    "title": "Comparing Postprandial Glycemic Control Using Fiasp vs Insulin Aspart in Hospitalized Patients With Type 2 Diabetes.",
    "xml": "<Element 'PubmedArticle' at 0x788503f19c60>"
}